Role of novel T-cell costimulatory pathways in transplantation

Current Opinion in Organ Transplantation

Volumn 8, Issue 1, 2003, Pages 25-33

  Mandelbrot, Didier A ^a   Sayegh, Mohamed H ^b  

^a UMMHC   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 28544435685     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/00075200-200303000-00006     Document Type: Review

References (125)

1. Bretscher P, Cohn M: A theory of self-nonself discrimination. Science 1970, 169:1042-1049.
2. Lafferty KJ, Cunningham AJ: A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975, 53:27-42.
3. Sayegh MH, Turka LA: The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998, 338:1813-1821.
4. Yamada A, Salama AD, Sayegh MH: The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002, 13:559-575.
5. Sharpe AH, Freeman GJ: The B7-CD28 superfamily. Nat Rev Immunol 2002, 2:116-126.
6. Salomon B, Bluestone JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001, 19:225-252.
7. Lenschow DJ, Walunas TL, Bluestone JA: CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996, 14:233-258.
8. Oosterwegel MA, Greenwald RJ, Mandelbrot DA, et al.: CTLA-4 and T cell activation. Curr Opin Immunol 1999, 11:294-300.
9. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al.: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 1992, 257:789-792.
10. Turka LA, Linsley PS, Lin H, et al.: T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci U S A 1992, 89:11102-11105.
11. Larsen CP, Elwood ET, Alexander DZ, et al.: Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996, 381:434-438.
12. Pearson TC, Alexander DZ, Winn KJ, et al.: Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994, 57:1701-1706.
13. Sayegh MH, Akalin E, Hancock WW, et al.: CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995, 181:1869-1874.
14. Kirk AD, Harlan DM, Armstrong NN, et al.: CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997, 94:8789-8794.
15. Levisetti MG, Padrid PA, Szot GL, et al.: Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997, 159:5187-5191.
16. Russell ME, Hancock WW, Akalin E, et al.: Chronic cardiac rejection in the LEW to F344 rat model: blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 1996, 97:833-838.
17. Azuma H, Chandraker A, Nadeau K, et al.: Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci U S A 1996, 93:12439-12444.
18. Chandraker A, Azuma H, Nadeau K, et al.: Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998, 101:2309-2318.
19. Sayegh MH, Zheng XG, Magee C, et al.: Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. Transplantation 1997, 64:1646-1650.
20. Mandelbrot DA, Furukawa Y, McAdam AJ, et al.: Expression of B7 molecules in recipient, not donor, mice determines the survival of cardiac allografts. J Immunol 1999, 163:3753-3757.
21. Sayegh MH: Finally, CTLA4Ig graduates to the clinic. J Clin Invest 1999, 103:1223-1225.
22. Perez VL, Van Parijs L, Biuckians A, et al.: Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997, 6:411-417.
23. Greenwald RJ, Boussiotis VA, Lorsbach RB, et al.: CTLA-4 regulates induction of anergy in vivo. Immunity 2001, 14:145-155.
24. Judge TA, Wu Z, Zheng XG, et al.: The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol 1999, 162:1947-1951.
25. Markees TG, Phillips NE, Gordon EJ, et al.: Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J Clin Invest 1998, 101:2446-2455.
26. Sho M, Yamada A, Najafian N, et al.: Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25(+) cells, and the alloreactive T cell clone size. J Immunol 2002, 169:3744-3751.
27. Ikemizu S, Gilbert RJ, Fennelly JA, et al.: Structure and dimerization of a soluble form of B7-1. Immunity 2000, 12:51-60.
28. Lenschow DJ, Zeng Y, Hathcock KS, et al.: Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation 1995, 60:1171-1178.
29. Yamada A, Kishimoto K, Dong VM, et al.: CD28-independent costimulation of T cells in alloimmune responses. J Immunol 2001, 167:140-146.
30. Mandelbrot DA, Oosterwegel MA, Shimizu K, et al.: B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4. J Clin Invest 2001, 107:881-887.
31. Durie FH, Foy TM, Masters SR, et al.: The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994, 15:406-411.
32. Blotta MH, Marshall JD, DeKruyff RH, et al.: Cross-linking of the CD40 ligand on human CD4+ T lymphocytes generates a costimulatory signal that upregulates IL-4 synthesis. J Immunol 1996, 156:3133-3140.
33. Blair PJ, Riley JL, Harlan DM, et al.: CD40 ligand (CD154) triggers a shortterm CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med 2000, 191:651-660.
34. Parker DC, Greiner DL, Phillips NE, et al.: Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci U S A 1995, 92:9560-9564.
35. Hancock WW, Sayegh MH, Zheng XG, et al.: Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci U S A 1996, 93:13967-13972.
36. Shimizu K, Schonbeck U, Mach F, et al.: Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol 2000, 165:3506-3518.
37. Hancock WW, Buelow R, Sayegh MH, et al.: Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and antiapoptotic genes. Nat Med 1998, 4:1392-1396.
38. Wekerle T, Kurtz J, Ito H, et al.: Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000, 6:464-469.
39. Durham MM, Bingaman AW, Adams AB, et al.: Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000, 165:1-4.
40. Kenyon NS, Chatzipetrou M, Masetti M, et al.: Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti- CD154. Proc Natl Acad Sci U S A 1999, 96:8132-8137.
41. Kawai T, Cosimi AB, Colvin RB, et al.: Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995, 59:256-262.
42. Newell KA, He G, Guo Z, et al.: Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells. J Immunol 1999, 163:2358-2362.
43. Trambley J, Bingaman AW, Lin A, et al.: Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999, 104:1715-1722.
44. Ensminger SM, Witzke O, Spriewald BM, et al.: CD8+ T cells contribute to the development of transplant arteriosclerosis despite CD154 blockade. Transplantation 2000, 69:2609-2612.
45. Hutloff A, Dittrich AM, Beier KC, et al.: ICOS is an inducible T-cell costimulator structurally and functionally related to CD28. Nature 1999, 397:263-266.
46. Swallow MM, Wallin JJ, Sha WC: B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity 1999, 11:423-432.
47. Yoshinaga SK, Whoriskey JS, Khare SD, et al.: T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999, 402:827-832.
48. Ling V, Wu PW, Finnerty HF, et al.: Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor. J Immunol 2000, 164:1653-1657.
49. Brodie D, Collins AV, Iaboni A, et al.: LICOS, a primordial costimulatory ligand? Curr Biol 2000, 10:333-336.
50. Beier KC, Hutloff A, Dittrich AM, et al.: Induction, binding specificity and function of human ICOS. Eur J Immunol 2000, 30:3707-3717.
51. McAdam AJ, Chang TT, Lumelsky AE, et al.: Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol 2000, 165:5035-5040.
52. McAdam AJ, Greenwald RJ, Levin MA, et al.: ICOS is critical for CD40- mediated antibody class switching. Nature 2001, 409:102-105.
53. Coyle AJ, Lehar S, Lloyd C, et al.: The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 2000, 13:95-105.
54. Coyle AJ, Gutierrez-Ramos JC: The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001, 2:203-209.
55. Tafuri A, Shahinian A, Bladt F, et al.: ICOS is essential for effective T-helpercell responses. Nature 2001, 409:105-109.
56. Dong C, Juedes AE, Temann UA, et al.: ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001, 409:97-101.
57. Khayyamian S, Hutloff A, Buchner K, et al.: ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine secretion by memory CD4+ T cells. Proc Natl Acad Sci U S A 2002, 99:6198-6203.
58. Wahl P, Schoop R, Bilic G, et al.: Renal tubular epithelial expression of the costimulatory molecule B7RP-1 (inducible costimulator ligand). J Am Soc Nephrol 2002, 13:1517-1526.
59. Ozkaynak E, Gao W, Shemmeri N, et al.: Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol 2001, 2:591-596.
60. Guo L, Li XK, Funeshima N, et al.: Prolonged survival in rat liver transplantation with mouse monoclonal antibody against an inducible costimulator (ICOS). Transplantation 2002, 73:1027-1032.
61. Freeman GJ, Long AJ, Iwai Y, et al.: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027-1034.
62. Latchman Y, Wood CR, Chernova T, et al.: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001, 2:261-268.
63. Dong H, Zhu G, Tamada K, et al.: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999, 5:1365-1369.
64. Nishimura H, Nose M, Hiai H, et al.: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11:141-151.
65. Tseng SY, Otsuji M, Gorski K, et al.: B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001, 193:839-846.
66. Pollok KE, Kim YJ, Zhou Z, et al.: Inducible T cell antigen 4-1BB: analysis of expression and function. J Immunol 1993, 150:771-781.
67. Melero I, Johnston JV, Shufford WW, et al.: NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998, 190:167-172.
68. Goodwin RG, Din WS, Davis-Smith T, et al.: Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 1993, 23:2631-2641.
69. DeBenedette MA, Shahinian A, Mak TW, et al.: Costimulation of CD28-T lymphocytes by 4-1BB ligand. J Immunol 1997, 158:551-559.
70. Pollok KE, Kim YJ, Hurtado J, et al.: 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells. Eur J Immunol 1994, 24:367-374.
71. Langstein J, Michel J, Fritsche J, et al.: CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. J Immunol 1998, 160:2488-2494.
72. Kim YJ, Kim SH, Mantel P, et al.: Human 4-1BB regulates CD28 costimulation to promote Th1 cell responses. Eur J Immunol 1998, 28:881-890.
73. Cannons JL, Lau P, Ghumman B, et al.: 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 2001, 167:1313-1324.
74. Blazar BR, Kwon BS, Panoskaltsis-Mortari A, et al.: Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J Immunol 2001, 166:3174-3183.
75. Shuford WW, Klussman K, Tritchler DD, et al.: 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997, 186:47-55.
76. Tan JT, Ha J, Cho HR, et al.: Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses. Transplantation 2000, 70:175-183.
77. Takahashi C, Mittler RS, Vella AT: Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999, 162:5037-5040.
78. DeBenedette MA, Wen T, Bachmann MF, et al.: Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J Immunol 1999, 163:4833-4841.
79. Hurtado JC, Kim SH, Pollok KE, et al.: Potential role of 4-1BB in T cell activation: comparison with the costimulatory molecule CD28. J Immunol 1995, 155:3360-3367.
80. DeBenedette MA, Chu NR, Pollok KE, et al.: Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP. J Exp Med 1995, 181:985-992.
81. Mauri DN, Ebner R, Montgomery RI, et al.: LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998, 8:21-30.
82. Zhai Y, Guo R, Hsu TL, et al.: LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest 1998, 102:1142-1151.
83. Tamada K, Shimozaki K, Chapoval AI, et al.: LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 2000, 164:4105-4110.
84. Tamada K, Shimozaki K, Chapoval AI, et al.: Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med 2000, 6:283-289.
85. Wang J, Lo JC, Foster A, et al.: The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J Clin Invest 2001, 108:1771-1780.
86. Tamada K, Ni J, Zhu G, et al.: Cutting edge: selective impairment of CD8+ T cell function in mice lacking the TNF superfamily member LIGHT. J Immunol 2002, 168:4832-4835.
87. Tamada K, Tamura H, Flies D, et al.: Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest 2002, 109:549-557.
88. Ye Q, Fraser CC, Gao W, et al.: Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival. J Exp Med 2002, 195:795-800.
89. Guo Z, Wang J, Meng L, et al.: Cutting edge: membrane lymphotoxin regulates CD8(+) T cell-mediated intestinal allograft rejection. J Immunol 2001, 167:4796-4800.
90. Lens SM, Tesselaar K, van Oers MH, et al.: Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol 1998, 10:491-499.
91. Hintzen RQ, Lens SM, Lammers K, et al.: Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol 1995, 154:2612-2623.
92. Takeda K, Oshima H, Hayakawa Y, et al.: CD27-mediated activation of murine NK cells. J Immunol 2000, 164:1741-1745.
93. Hendriks J, Gravestein LA, Tesselaar K, et al.: CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 2000, 1:433-440.
94. Douin-Echinard V, Bornes S, Rochaix P, et al.: The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status. Cancer Gene Ther 2000, 7:1543-1556.
95. Braun-Falco M, Hallek M: Recombinant adeno-associated virus (rAAV) vector- mediated cotransduction of CD70 and CD80 into human malignant melanoma cells results in an additive T-cell response. Arch Dermatol Res 2001, 293:12-17.
96. Nakajima A, Oshima H, Nohara C, et al.: Involvement of CD70-CD27 interactions in the induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 2000, 109:188-196.
97. Akiba H, Oshima H, Takeda K, et al.: CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. J Immunol 1999, 162:7058-7066.
98. Yamada A, Sho M, Najafian N, et al.: A critical role for the CD27-CD70 pathway in CD28 independent alloimmune responses. Am J Transplant 2002, 2:231.
99. Mallett S, Fossum S, Barclay AN: Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes-a molecule related to nerve growth factor receptor. EMBO J 1990, 9:1063-1068.
100. Gramaglia I, Weinberg AD, Lemon M, et al.: Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998, 161:6510-6517.
101. Calderhead DM, Buhlmann JE, van den Eertwegh AJ, et al.: Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. J Immunol 1993, 151:5261-5271.
102. Ohshima Y, Tanaka Y, Tozawa H, et al.: Expression and function of OX40 ligand on human dendritic cells. J Immunol 1997, 159:3838-3848.
103. Imura A, Hori T, Imada K, et al.: The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med 1996, 183:2185-2195.
104. Kopf M, Ruedl C, Schmitz N, et al.: OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL responses after virus infection. Immunity 1999, 11:699-708.
105. Rogers PR, Song J, Gramaglia I, et al.: OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001, 15:445-455.
106. Stuber E, Neurath M, Calderhead D, et al.: Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 1995, 2:507-521.
107. Nohara C, Akiba H, Nakajima A, et al.: Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells. J Immunol 2001, 166:2108-2115.
108. Higgins LM, McDonald SA, Whittle N, et al.: Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol 1999, 162:486-493.
109. Chitnis T, Najafian N, Abdallah KA, et al.: CD28-independent induction of experimental autoimmune encephalomyelitis. J Clin Invest 2001, 107:575-583.
110. Tsukada N, Akiba H, Kobata T, et al.: Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood 2000, 95:2434-2439.
111. Wu T, Hering B, Kirchof N, et al.: The effect of OX40/OX40L and CD27/CD70 pathways on allogeneic islet graft rejection. Transplant Proc 2001, 33:217-218.
112. Yuan X, Salama A, Dong V, et al.: The important role of CD134-CD134L costimulatory signal in CD28-B7 independent allograft rejection. Am J Transplant 2002, 2:230.
113. Schwab U, Stein H, Gerdes J, et al.: Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982, 299:65-67.
114. Bowen MA, Lee RK, Miragliotta G, et al.: Structure and expression of murine CD30 and its role in cytokine production. J Immunol 1996, 156:442-449.
115. Gilfillan MC, Noel PJ, Podack ER, et al.: Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol 1998, 160:2180-2187.
116. Smith CA, Gruss HJ, Davis T, et al.: CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993, 73:1349-1360.
117. Gruss HJ, Boiani N, Williams DE, et al.: Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994, 83:2045-2056.
118. Telford WG, Nam SY, Podack ER, et al.: CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals. Cell Immunol 1997, 182:125-136.
119. Amakawa R, Hakem A, Kundig TM, et al.: Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 1996, 84:551-562.
120. Kurts C, Carbone FR, Krummel MF, et al.: Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 1999, 398:341-344.
121. Beckmann J, Kurts C, Klebba I, et al.: The role of CD30 in skin and heart allograft rejection in the mouse. Transplant Proc 2001, 33:140-141.
122. Lee SY, Park CG, Choi Y: T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med 1996, 183:669-674.
123. Del Prete G, De Carli M, Almerigogna F, et al.: Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J 1995, 9:81-86.
124. Hamann D, Hilkens CM, Grogan JL, et al.: CD30 expression does not discriminate between human Th1- and Th2-type T cells. J Immunol 1996, 156:1387-1391.
125. Salama AD, Remuzzi G, Harmon WE, et al.: Challenges to achieving clinical transplantation tolerance. J Clin Invest 2001, 108:943-948.